NCT03804515: A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 90 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: If patients are not HER2+, their tumor must express EGFR
Exclusions: Patients with untreated unstable brain metastases – see trial for details; Patients with prior exposure to poziotinib

Comments are closed.

Up ↑